Efruxifermin
Phase 3Protein / enzyme
Akero TherapeuticsEfruxifermin is a protein / enzyme that works as a FGF21 Fc Fusion.[2] It is being investigated across 5 indications, with its most advanced program in Phase 3.[1]
Efruxifermin is one of 151 fusion protein programs targeting Hepatitis. It is currently in Phase 3.
5
Indications
4
Total Trials
3
Active Trials
150
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
252 competitors in Cirrhosis
#DrugCompanyPhaseTrials
1Efruxifermin
Akero TherapeuticsPhase 3
Proamatine
TakedaPreclinical
Farxiga
AstraZenecaPreclinical
Thalomid
Bristol-Myers SquibbPreclinical
Revia
TevaPreclinical
Cipro
BayerPreclinical
Azulfidine
PfizerPreclinical
HEPCLUDEX
GileadPreclinical
Cialis
Eli LillyPreclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Alcoholic Fatty Liver Disease1 trial
Cirrhosis1 trial
Hepatitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Efruxifermin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- FGF21 Fc Fusion[2]
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company